Beating the Odds: Emergency Liver Transplants and the Future of High-Risk Patients
"How a modified ABO-incompatible transplant protocol offers hope for patients with ultrahigh MELD scores."
For individuals facing acute-on-chronic liver failure, the clock is ticking. When conventional treatments fail, a liver transplant can be the only lifeline. However, patients with ultrahigh Model for End-Stage Liver Disease (MELD) scores, indicating severe liver dysfunction, often face a daunting reality: their condition is deemed too risky for standard transplant procedures, including those involving ABO-compatible donors. The complexities of their illness, frequently compounded by infections and organ dysfunction, present significant challenges.
A recent study published in Hepatobiliary & Pancreatic Diseases International details a case where a 49-year-old Chinese man, battling acute-on-chronic hepatitis B, was successfully treated with an emergency ABO-incompatible (ABOi) living donor liver transplant (LDLT). This procedure, typically avoided due to the risk of rejection, was carefully executed using a modified protocol to overcome the blood type mismatch. The patient's MELD score of 40 placed him in a critical state, highlighting the innovative approach's potential to save lives when all other options seem exhausted.
This article dives into the details of this groundbreaking case, exploring the modified ABOi LDLT protocol, the challenges faced by the medical team, and the broader implications for patients with severe liver failure. Discover how this approach offers a beacon of hope for those with ultrahigh MELD scores, potentially reshaping the future of liver transplantation.
Transplant Volume and ABO-Incompatible Options
The OPTN/SRTR 2024 Annual Data Report records 11,458 liver transplants in the United States in 2024, a record high and a 70.3% increase since 2014. Adults received 10,886 transplants (95.0%) and children received 572 (5.0%); living donation accounted for 4.5% of adult and 19.4% of pediatric transplants. With limited deceased-donor liver availability, ABO-incompatible living-donor transplantation is discussed as a way to expand the donor pool, though it was historically viewed as carrying inferior postoperative outcomes.
Matching and Expanding the Donor Pool
ABO blood-type-matched transplantation is commonly performed in deceased-donor liver transplantation, while the supply of donors remains limited. Liver transplantation is described as a definitive treatment for decompensated cirrhosis and fulminant liver failure. ABO-incompatible living-donor transplantation can help expand the donor pool, but the cited material does not specify its outcomes or limitations in enough detail to quantify them.
From Contraindication to Developing Practice
ABO-incompatible liver transplantation using conventional immunosuppression was considered a contraindication because antibody-mediated complications could lead to graft loss. A historical review notes that the number of patients benefiting from ABO-incompatible renal and liver transplants increased gradually after developments reported by Alexandre and colleagues in 1985. The available source material identifies this milestone but does not provide further details about the specific developments.
Navigating the Risks: The Modified ABOi LDLT Protocol
ABOi LDLT involves transplanting a liver from a donor with an incompatible blood type. The primary risk is antibody-mediated rejection, where the recipient's immune system attacks the new organ. To mitigate this, the medical team employed a carefully orchestrated protocol that included:
- Rituximab: Administered two weeks before the transplant to deplete B cells, which produce antibodies.
- Plasma Exchange: Repeatedly performed to remove existing anti-B antibodies from the patient's blood. Fresh frozen plasma from AB-positive donors (compatible with both A and B blood types) was used to replenish the blood volume.
- Mycophenolate Mofetil (MMF): Given a week prior to the transplant, MMF is an immunosuppressant medication that further helps to prevent rejection. Dosage was carefully adjusted considering the patient’s pre-existing infection.
- Antibiotics and Antifungals: Given to combat existing infections (bacteremia and spontaneous bacterial peritonitis) and prevent new ones.
- Basiliximab and Steroids: Used for induction immunosuppression immediately following the transplant.
- Tacrolimus and Prednisolone: Used for ongoing maintenance of immunosuppression, preventing rejection while allowing the body to heal.
Recent Review of Pediatric Outcomes
A systematic review and meta-analysis published online August 27, 2026, reports that ABO-incompatible liver transplantation in children achieves patient and graft survival comparable to ABO-compatible transplantation. The review addresses continuing concerns about immunological, vascular, and biliary complications. Separately, a study of adult and pediatric liver transplants performed from 1987 through 2022 set out to reassess ABO-incompatible transplantation as an underused graft supply; the supplied abstract does not give its results.
Comparing Outcomes and Complications
ABO-incompatible liver transplantation has been used to address donor shortages, but its advantages and disadvantages relative to ABO-compatible transplantation remain subjects of outcome research. A systematic review and meta-analysis evaluated differences between ABO-incompatible and ABO-compatible liver transplantation using eligible studies published before November 28; the supplied snippet does not state its findings. A separate 2021 study compared short- and long-term outcomes between the two cohorts, but its snippet likewise provides no results, so specific complication rates or survival differences cannot be concluded from these materials.
Evidence Does Not Match the Article Topic
The supplied comparative-analysis sources concern pancreaticoduodenectomy, not emergency liver transplantation or ABO-incompatible liver transplantation. One reports that profitability was achieved in 29% of patients undergoing robotic pancreaticoduodenectomy since 2016. Another reports lower morbidity in Group A than Group B (24% versus 36%) and shorter hospitalization (11 versus 16 days) in a case-control study of preoperative biliary drainage. These findings do not support a comparison of liver-transplant approaches.
A Glimmer of Hope: What This Means for the Future
The successful outcome of this case study offers a significant glimmer of hope for patients with ultrahigh MELD scores who might otherwise be denied a life-saving transplant. By carefully modifying the ABOi LDLT protocol, medical teams can potentially overcome the blood type barrier and offer a chance at survival to those in critical need.
Trends Shaping Liver Transplantation
A review of current trends and future directions describes substantial transformation in U.S. liver transplantation over the past decade. It attributes this change to shifting disease epidemiology, therapeutic advancements, and innovations in organ preservation. The supplied material does not specify particular future technologies or projections.
A Reported ABO-Incompatible Transplant Case
A 2023 case report describes an end-stage liver disease patient co-infected with hepatitis B and HIV who underwent ABO-incompatible living-donor liver transplantation. The report says this procedure had not previously been documented in the context of RDD. The transplant was preceded by desensitization with rituximab and immunoadsorption, and the patient had a satisfactory postoperative course. A separate 2025 case report also describes ABO-incompatible living-donor transplantation after rituximab and immunoadsorption, followed by a satisfactory postoperative course.
The authors emphasize that controlling underlying infections is paramount to the success of this procedure. The patient's pre-existing sepsis required aggressive antimicrobial treatment both before and after the transplant. This highlights the importance of a multidisciplinary approach involving transplant surgeons, hepatologists, hematologists, microbiologists, and anesthesiologists.
While this case study is encouraging, further research is needed to refine the ABOi LDLT protocol and identify the ideal candidates for this approach. However, it represents a significant step forward in the field of liver transplantation, offering new possibilities for patients who were previously considered too high-risk. As protocols evolve, minimized immunosuppression regimens are also being explored, potentially reducing long-term side effects and improving patient outcomes.